Frequency of Treatment Patterns of Kidney Protective Therapies among Patients with Chronic Kidney Disease at Tertiary Care Hospital, Karachi.
DOI:
https://doi.org/10.51985/JBUMDC2025783Keywords:
Angiotensin-Converting Enzyme Inhibitors; Angiotensin ReceptorAbstract
Objective: To determine the frequency and treatment patterns of kidney-protective therapies, including ACE inhibitors,
ARBs, and SGLT2 inhibitors, among patients with chronic kidney disease (CKD) at a tertiary care hospital in Karachi.
Study Design and Setting: This cross-sectional study was conducted in the Department of Nephrology, Aga Khan University
Hospital, Karachi, from 12TH May 2025 to 10th October 2025.
Methodology: A non-probability consecutive sampling was used to recruit 133 clinically confirmed CKD patients aged
40-80 years. Demographic information, clinical features, lifestyle, and kidney-protective drugs were documented using a
structured proforma. Anthropometric measurements were made following standard procedures and the status of smoking
and physical activity was determined by interviewing the patients. Prescriptions and comorbidities were proven by medical
records. The data were analyzed using SPSS version 22 descriptive statistics and chi-square/Fisher exact test, p<0.05 was
significant.
Results: Of the 133 patients, 68.4% were aged 61–80 years, and 51.1% were female. ACE inhibitors were prescribed to
39.8% of patients, ARBs to 15%, and SGLT2 inhibitors to 34.6%. The use of ACE inhibitors was significantly higher
among patients with diabetic nephropathy and those with a shorter duration of disease. SGLT2 inhibitor prescriptions were
more common in younger and urban populations and among diabetic patients, suggesting awareness of newer therapeutic
options.
Conclusion: Patients with CKD were undertreated with key kidney-protective therapies, particularly ARBs and SGLT2
inhibitors. Younger, diabetic, and urban patients were more likely to receive evidence-based treatments, indicating gaps
in guideline adherence and inequitable access.
References
1. Kim SM, Jung JY. Nutritional management in patients with
chronic kidney disease. Korean J Intern Med. 2020;35(6):1279-
90. DOI: https://doi.org/10.3904/kjim.2020.408
2. Machado-Duque ME, Gaviria-Mendoza A, Valladales-Restrepo
LF, Franco JS, Forero MR, Vizcaya D, et al. Treatment patterns
of antidiabetic and kidney protective therapies among patients
with type 2 diabetes mellitus and chronic kidney disease in
Colombia: The KDICO descriptive study. Diabetol Metab
Syndr. 2023;15(1):150. DOI: https://doi.org/10.1186/s13098-
023-01126-6
3. Liyanage T, Toyama T, Hockham C, Ninomiya T, Perkovic
V, Woodward M, et al. Prevalence of chronic kidney disease
in Asia: A systematic review and analysis. BMJ Glob Health.
2022;7(1):e007525. DOI: https://doi.org/10.1136/bmjgh-2022-
007525
4. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM,
Bruemmer D, et al. Chronic kidney disease and risk
management: Standards of care in diabetes—2023. Diabetes
Care. 2023;46(Suppl 1):S191-S202. DOI: https://doi.org/
10.2337/dc23-S011
5. Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY,
Wanner C, et al. Diabetic kidney disease: A clinical update
from Kidney Disease: Improving Global Outcomes. Kidney
Int. 2015;87(1):20-30. DOI: https://doi.org/ 10.1038/
ki.2014.128
6. Nagasu H, Yano Y. Kidney outcomes associated with SGLT2
inhibitors versus other glucose- lowering drugs in real-world
clinical practice: The Japan Chronic Kidney Disease Database.
Diabetes Care. 2021;44(11):2542-51. DOI: https://doi.org/
10.2337/dc21-1081
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch
WE, Parving HH, et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med. 2001;345(12):861-69. DOI:
https://doi.org/10.1056/NEJMoa011161
8. Bailey CJ, Day C, Bellary S. Renal protection with SGLT2
inhibitors: Effects in acute and chronic kidney disease. Curr
Diabetes Rep. 2022;22(1):39-52. DOI: https://doi.org/10.1007
/s11892-021- 01442-z
9. Fried LF, Petruski-Ivleva N, Folkerts K, Schmedt N, Velentgas
P, Kovesdy CP. ACE inhibitor or ARB treatment among
patients with diabetes and chronic kidney disease. Am J Manag
Care. 2021;27(20 Suppl):S360-S368. DOI: https://doi.org/
10.37765/ajmc.2021.8880
10. Kamath LG, HN G, HS S. A study of drug utilisation pattern
in patients of chronic kidney disease at a tertiary care hospital.
Int J Basic Clin Pharmacol. 2019;8(2):170-75. DOI: https://
doi.org/10.18203/2319-2003.ijbcp20190131
11. Ahlawat R, D’Cruz S, Tiwari P. Drug utilization pattern in
chronic kidney disease patients at a tertiary care public teaching
hospital: Evidence from a cross-sectional study. J Pharm Care
Health Syst. 2015;3(1):1-5. DOI: https://doi.org/10.4172/2376-
0419.1000149
12. Al-Jabri MM, Shastry CS, Chand S. Assessment of drug
utilisation pattern in chronic kidney disease patients in a
tertiary care hospital based on WHO core drug use indicators.
J Glob Pharma Technol. 2019;11(9):1-9.
13. Prasad N, Yadav AK, Kundu M, Sethi J, Jaryal A, Sircar D,
et al. Prescription practices in patients with mild to moderate
CKD in India. Kidney Int Rep. 2021;6(9):2455-62. DOI:
https://doi.org/10.1016/j.ekir.2021.06.011
14. Hadia R, Rajput HS, Mehta V, Shah P, Muley A, Thakkar J,
et al. An observational study on drug utilisation pattern in
chronic kidney disease patients using antihypertensive drugs
in a tertiary care teaching hospital. J Pharm Res Int.
2021;33(35B):9-18. DOI: https://doi.org/10.9734/ jpri/2021/
v33i35B31893
15. Mwenda V, Githuku J, Gathecha G, Wambugu BM, Roka ZG,
Ong’or WO. Prevalence and factors associated with chronic
kidney disease among medical inpatients at the Kenyatta
National Hospital, Kenya, 2018: A cross-sectional study. Pan
Afr Med J. 2019;33:321. DOI: https://doi.org/10.11604 /pamj.
2019.33.321.18114
16. Parvin S, Akter N, Rizvi HM, Afroz R, Biswas R, Sultana M,
et al. Prescription pattern of antihypertensive drugs in chronic
kidney disease patients attending a tertiary care hospital. J
Comilla Med Coll Teachers Assoc. 2024;28(2):70-74. DOI:
https://doi.org/10.3329/jcomcta.v28i2.78015
17. Sarafidis PA, Sharpe CC, Wood E, Blacklock R, Rumjon A,
Al-Yassin A, et al. Prevalence, patterns of treatment, and
control of hypertension in predialysis patients with chronic
kidney disease. Nephron Clin Pract. 2012;120(3):c147-55.
DOI: https://doi.org/10.1159/000337571
18. Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2
inhibitors with cardiovascular, kidney, and safety outcomes
among patients with diabetic kidney disease: A meta-analysis.
Cardiovasc Diabetol. 2022;21:47. DOI: https://doi.org/10.
1186/s12933-022-01476-x
19. Roddick AJ, Wonnacott A, Webb D, et al. UK Kidney
Association Clinical Practice Guideline: Sodium-glucose cotransporter-2 (SGLT-2) inhibition in adults with kidney disease
– 2023 update. BMC Nephrol. 2023;24:310. DOI: https://doi.
org/10.1186/s12882-023-03339-3
20. Jamil S, Zainab A, Manjeet Singh A, et al. Efficacy and safety
of sodium-glucose cotransporter-2 (SGLT2) inhibitors in
patients with diabetes and chronic kidney disease: A metaanalysis of randomized control trials. Cureus. 2022;14(11):
e31898. DOI: https://doi.org/10.7759/ cureus.31898
21. An Y. SGLT-2 inhibitors: A deeper dive into their renal
protective properties beyond glycemic control and proteinuria
reduction. Am J Nephrol. 2025; (Online ahead of print). DOI:
https://doi.org/10.1159/000546079
22. Lai JW, Wang CC, Chou CY. SGLT-2 inhibitors in chronic
peritoneal dialysis patients: A follow- up study. BMC Nephrol.
2024;25:238. DOI: https://doi.org/10.1186/s12882-024-03683-
y
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sana Moin, Sonia Yaqub (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
